

PATENTS
11/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Varma, et al.

Serial No. 09/899,702

Filed: July 5, 2001

For: Estrogenic Compounds As
Antiangiogenic Agents

Art Unit: 1616

Examiner: Qazi, S.

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Responsive to the Restriction Requirement mailed September 14, 2001 in the above-identified patent application, Applicants elect to prosecute the invention of Group 1, Claims 1-9, drawn to compounds, classified in class 552, subclass 625, 626, 627 and others. Applicants elect the species of Claim 8. Claims 1, 2 and 8 are readable on the species.

The election is made with traverse. When claims to the compounds are allowed, Applicants reserve the right to re-enter claims to the method of using the compounds.

Respectfully submitted,
KILPATRICK STOCKTON LLP

By: Suzanne Seavello Shope
Registration No. 37,933

1100 Peachtree Street, N.E.
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Attorney Docket No. 43170-253406 (05213-0731)

I hereby certify that this correspondence is being deposited with the United States Postal Service via First Class Mail to the attention of Assistant Commissioner for Patents, Washington, DC 20231 on November 9, 2001.

Suzanne Seavello Shope - Reg. No. 37,933

DEC. 11. 2001 2:32PM

KILPATRICK STOCKTON

16c3

NO. 2189 P. 1



Attorneys at Law

December 11, 2001

FAX RECEIVED

DEC 11 2001

GROUP 1600

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
404 815 6500 F 404 815 6555
www.KilpatrickStockton.com

direct dial 404 745 2413

SShope@KilpatrickStockton.com

FAX

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE
Examiner Qazi (703) 305-3910	(703) 308-4556	U.S. Patent and Trademark Office Arlington, VA

OFFICIAL

Suzanne Seavello Shope (3287)

FROM

6

PAGES (WITH COVER)

05213-0731

REFERENCE NO

43170/253406

CLIENT/MATTER NO.

PLEASE CALL 404-745-2413 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

CONFIDENTIALITY NOTE:

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

With reference to our telephone conversation on December 7, 2001 regarding 09/779,331, attached are copies of the documents that were mailed to you on November 9, 2001.

1. Transmittal Sheet;
2. Response to Restriction Requirement;
3. Petition for One-Month Extension of Time;
4. Check for \$55.00.

With respect to 09/899,702, we have not filed the Response yet. If you have any questions, please do not hesitate to contact us.

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME:

COMPLETED BY:

JOB CODE

ATLANTA AUGUSTA BRUSSELS CHARLOTTE LONDON MIAMI RALEIGH RESTON STOCKHOLM WASHINGTON WINSTON-SALEM

The U.S. Patent & Trademark Office official Mailroom stamp affixed hereto,
acknowledges receipt of the items listed below:

Application No.: 09/779,331 Filing Date: February 8, 2001

Applicant: AGOSTON, ET AL.

Title: ANTIANGIOGENIC AGENTS

Papers Submitted:

**Transmittal Sheet; Response to Restriction Requirement; Petition
for Extension of Time (one month); and check in the amount of
\$55.00 to cover the cost of a one month extension**

Docket No.: 43170-253406 (05213-0731) Atty/Sec'y: SSS/pdo

Date Mailed: November 9, 2001

Express Mail Label No.: N/A

PATENTS

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No. 43170-253406 (05213-0731)

Agoston, et al.

Serial No. 09/779,331

Filed: February 8, 2001

For: Antiangiogenic Agents

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Transmitted herewith is a paper in the above-identified application.

- Response to Restriction Requirement
 Petition for Extension of Time (one month)
 Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement.
 Applicant claims small entity status.
 The additional fee is calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE	RATE	ADDITIONAL FEE
TOTAL	9	MINUS	20=	0	x9	\$0	x18	\$
INDEP.	1	MINUS	3=	0	x42	\$0	x84	\$
FIRST PRESENTATION OF <input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+140	\$	+280	\$
					TOTAL ADDITIONAL FEE	\$0		\$

- A check in the amount of \$55.00 is attached.
 The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on November 9, 2001.

Suzanne Scavullo Shope
Signature

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
Telephone: 404/815-6500

By: Suzanne Scavullo Shope
Suzanne Scavullo Shope, Attorney for Applicant
Reg. No. 37,933